Is RCKT or ANIX more profitable?

Rocket Pharmaceuticals' return on equity of -52.77% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Rocket Pharmaceuticals N/A -52.77% -44.92% Anixa Biosciences N/A -76.59% -67.80%

Does the media prefer RCKT or ANIX?

In the previous week, Anixa Biosciences had 2 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 7 mentions for Anixa Biosciences and 5 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.60 beat Anixa Biosciences' score of -0.52 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anixa Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative

Is PRLD or ANIX more profitable?

Prelude Therapeutics' return on equity of -75.35% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -75.35% -44.39% Anixa Biosciences N/A -76.59% -67.80%

Does the media prefer PRLD or ANIX?

In the previous week, Anixa Biosciences had 4 more articles in the media than Prelude Therapeutics. MarketBeat recorded 7 mentions for Anixa Biosciences and 3 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 0.11 beat Anixa Biosciences' score of -0.52 indicating that Prelude Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Anixa Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative

Is ANIX or DMAC more profitable?

Anixa Biosciences' return on equity of -76.59% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -76.59% -67.80% DiaMedica Therapeutics N/A -77.76% -69.43%

Does the media refer more to ANIX or DMAC?

In the previous week, Anixa Biosciences had 4 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 7 mentions for Anixa Biosciences and 3 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.67 beat Anixa Biosciences' score of -0.52 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative DiaMedica Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ANIX or CYPH more profitable?

Cypherpunk Technologies' return on equity of -20.76% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -76.59% -67.80% Cypherpunk Technologies N/A -20.76% -19.48%

Does the media prefer ANIX or CYPH?

In the previous week, Anixa Biosciences had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 7 mentions for Anixa Biosciences and 6 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 0.32 beat Anixa Biosciences' score of -0.52 indicating that Cypherpunk Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative Cypherpunk Technologies 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ANIX or OCGN more profitable?

Anixa Biosciences' return on equity of -76.59% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -76.59% -67.80% Ocugen N/A -127,987.80% -115.95%

Does the media prefer ANIX or OCGN?

In the previous week, Anixa Biosciences had 5 more articles in the media than Ocugen. MarketBeat recorded 7 mentions for Anixa Biosciences and 2 mentions for Ocugen. Ocugen's average media sentiment score of 1.24 beat Anixa Biosciences' score of -0.52 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative Ocugen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Anixa Biosciences (ANIX) Competitors

$2.78 +0.03 (+1.09%)

As of 04:00 PM Eastern

Compare

ANIX vs. RCKT, PRLD, DMAC, CYPH, and OCGN

Should you buy Anixa Biosciences stock or one of its competitors? Anixa Biosciences's main competitors and comparable companies include Rocket Pharmaceuticals (RCKT), Prelude Therapeutics (PRLD), DiaMedica Therapeutics (DMAC), Cypherpunk Technologies (CYPH), and Ocugen (OCGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Anixa Biosciences compare to Rocket Pharmaceuticals?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Anixa Biosciences has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Anixa Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A
Anixa Biosciences	$210K	460.16	-$10.93M	-$0.32	N/A

In the previous week, Anixa Biosciences had 2 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 7 mentions for Anixa Biosciences and 5 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.60 beat Anixa Biosciences' score of -0.52 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anixa Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative

Rocket Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

Rocket Pharmaceuticals currently has a consensus price target of $8.63, indicating a potential upside of 220.63%. Anixa Biosciences has a consensus price target of $8.00, indicating a potential upside of 187.77%. Given Rocket Pharmaceuticals' higher possible upside, equities analysts plainly believe Rocket Pharmaceuticals is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.36
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 21.3% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Rocket Pharmaceuticals' return on equity of -52.77% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%
Anixa Biosciences	N/A	-76.59%	-67.80%

Summary

Rocket Pharmaceuticals beats Anixa Biosciences on 8 of the 15 factors compared between the two stocks.

How does Anixa Biosciences compare to Prelude Therapeutics?

Prelude Therapeutics (NASDAQ:PRLD) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Prelude Therapeutics' return on equity of -75.35% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-75.35%	-44.39%
Anixa Biosciences	N/A	-76.59%	-67.80%

Anixa Biosciences has lower revenue, but higher earnings than Prelude Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	26.23	-$99.50M	-$0.73	N/A
Anixa Biosciences	$210K	460.16	-$10.93M	-$0.32	N/A

In the previous week, Anixa Biosciences had 4 more articles in the media than Prelude Therapeutics. MarketBeat recorded 7 mentions for Anixa Biosciences and 3 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 0.11 beat Anixa Biosciences' score of -0.52 indicating that Prelude Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anixa Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative

Prelude Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 26.4% of Anixa Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Prelude Therapeutics presently has a consensus target price of $8.75, suggesting a potential upside of 119.30%. Anixa Biosciences has a consensus target price of $8.00, suggesting a potential upside of 187.77%. Given Anixa Biosciences' higher possible upside, analysts plainly believe Anixa Biosciences is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Prelude Therapeutics beats Anixa Biosciences on 10 of the 15 factors compared between the two stocks.

How does Anixa Biosciences compare to DiaMedica Therapeutics?

Anixa Biosciences (NASDAQ:ANIX) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Anixa Biosciences has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, DiaMedica Therapeutics has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

Anixa Biosciences has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Anixa Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	460.16	-$10.93M	-$0.32	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Anixa Biosciences had 4 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 7 mentions for Anixa Biosciences and 3 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.67 beat Anixa Biosciences' score of -0.52 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative
DiaMedica Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anixa Biosciences currently has a consensus target price of $8.00, indicating a potential upside of 187.77%. DiaMedica Therapeutics has a consensus target price of $12.00, indicating a potential upside of 53.26%. Given Anixa Biosciences' higher probable upside, analysts clearly believe Anixa Biosciences is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Anixa Biosciences' return on equity of -76.59% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-76.59%	-67.80%
DiaMedica Therapeutics	N/A	-77.76%	-69.43%

Summary

Anixa Biosciences beats DiaMedica Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Anixa Biosciences compare to Cypherpunk Technologies?

Anixa Biosciences (NASDAQ:ANIX) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Anixa Biosciences has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

In the previous week, Anixa Biosciences had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 7 mentions for Anixa Biosciences and 6 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 0.32 beat Anixa Biosciences' score of -0.52 indicating that Cypherpunk Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative
Cypherpunk Technologies	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cypherpunk Technologies' return on equity of -20.76% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-76.59%	-67.80%
Cypherpunk Technologies	N/A	-20.76%	-19.48%

Anixa Biosciences presently has a consensus target price of $8.00, suggesting a potential upside of 187.77%. Cypherpunk Technologies has a consensus target price of $4.90, suggesting a potential upside of 20.10%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Anixa Biosciences is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cypherpunk Technologies has lower revenue, but higher earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	460.16	-$10.93M	-$0.32	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	7.29

Summary

Anixa Biosciences and Cypherpunk Technologies tied by winning 7 of the 14 factors compared between the two stocks.

How does Anixa Biosciences compare to Ocugen?

Anixa Biosciences (NASDAQ:ANIX) and Ocugen (NASDAQ:OCGN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

Anixa Biosciences has higher earnings, but lower revenue than Ocugen. Anixa Biosciences is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	460.16	-$10.93M	-$0.32	N/A
Ocugen	$4.41M	76.90	-$67.85M	-$0.26	N/A

Anixa Biosciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Ocugen has a beta of 2.2, suggesting that its share price is 120% more volatile than the broader market.

Anixa Biosciences currently has a consensus price target of $8.00, indicating a potential upside of 187.77%. Ocugen has a consensus price target of $9.50, indicating a potential upside of 850.00%. Given Ocugen's stronger consensus rating and higher probable upside, analysts plainly believe Ocugen is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Anixa Biosciences' return on equity of -76.59% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-76.59%	-67.80%
Ocugen	N/A	-127,987.80%	-115.95%

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by insiders. Comparatively, 4.0% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Anixa Biosciences had 5 more articles in the media than Ocugen. MarketBeat recorded 7 mentions for Anixa Biosciences and 2 mentions for Ocugen. Ocugen's average media sentiment score of 1.24 beat Anixa Biosciences' score of -0.52 indicating that Ocugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative
Ocugen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ocugen beats Anixa Biosciences on 8 of the 15 factors compared between the two stocks.

Get Anixa Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIX vs. The Competition

Export

Metric	Anixa Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$96.99M	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-8.69	14.00	274.40	25.76
Price / Sales	460.16	1,342.40	639.25	86.81
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	7.32	15.46	10.52	6.34
Net Income	-$10.93M	-$22.82M	$3.49B	$360.00M
7 Day Performance	0.72%	-2.21%	-1.08%	-0.11%
1 Month Performance	-23.20%	-6.66%	-3.39%	-3.42%
1 Year Performance	-19.19%	30.99%	15.08%	5.46%

Anixa Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIX Anixa Biosciences	3.5798 of 5 stars	$2.78 +1.1%	$8.00 +187.8%	-19.6%	$96.99M	$210K	N/A	4	Analyst Forecast
RCKT Rocket Pharmaceuticals	2.5629 of 5 stars	$3.43 -2.1%	$8.63 +151.8%	-2.6%	$376.00M	N/A	N/A	202
PRLD Prelude Therapeutics	2.2389 of 5 stars	$4.69 +2.5%	$8.75 +86.7%	+318.4%	$373.96M	$22.42M	N/A	79
DMAC DiaMedica Therapeutics	2.1427 of 5 stars	$6.90 +0.7%	$12.00 +74.0%	+10.2%	$371.85M	N/A	N/A	35	Positive News
CYPH Cypherpunk Technologies	2.7069 of 5 stars	$3.37 +9.8%	$4.90 +45.4%	+1,122.1%	$363.15M	N/A	6.02	40	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anixa Biosciences (ANIX) Competitors

ANIX vs. RCKT, PRLD, DMAC, CYPH, and OCGN

How does Anixa Biosciences compare to Rocket Pharmaceuticals?

Summary

How does Anixa Biosciences compare to Prelude Therapeutics?

Summary

How does Anixa Biosciences compare to DiaMedica Therapeutics?

Summary

How does Anixa Biosciences compare to Cypherpunk Technologies?

Summary

How does Anixa Biosciences compare to Ocugen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX vs. The Competition

Anixa Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anixa Biosciences (ANIX) Competitors

ANIX vs. RCKT, PRLD, DMAC, CYPH, and OCGN

How does Anixa Biosciences compare to Rocket Pharmaceuticals?

Which has preferable valuation and earnings, RCKT or ANIX?

Does the media prefer RCKT or ANIX?

Which has more volatility and risk, RCKT or ANIX?

Do analysts prefer RCKT or ANIX?

Do insiders & institutionals hold more shares of RCKT or ANIX?

Is RCKT or ANIX more profitable?

Summary

How does Anixa Biosciences compare to Prelude Therapeutics?

Is PRLD or ANIX more profitable?

Which has better valuation and earnings, PRLD or ANIX?

Does the media prefer PRLD or ANIX?

Which has more volatility & risk, PRLD or ANIX?

Do insiders and institutionals have more ownership in PRLD or ANIX?

Do analysts prefer PRLD or ANIX?

Summary

How does Anixa Biosciences compare to DiaMedica Therapeutics?

Which has more volatility & risk, ANIX or DMAC?

Which has preferable earnings and valuation, ANIX or DMAC?

Do insiders and institutionals believe in ANIX or DMAC?

Does the media refer more to ANIX or DMAC?

Do analysts prefer ANIX or DMAC?

Is ANIX or DMAC more profitable?

Summary

How does Anixa Biosciences compare to Cypherpunk Technologies?

Which has more risk & volatility, ANIX or CYPH?

Does the media prefer ANIX or CYPH?

Do institutionals and insiders have more ownership in ANIX or CYPH?

Is ANIX or CYPH more profitable?

Do analysts prefer ANIX or CYPH?

Which has preferable valuation & earnings, ANIX or CYPH?

Summary

How does Anixa Biosciences compare to Ocugen?

Which has better earnings & valuation, ANIX or OCGN?

Which has more volatility & risk, ANIX or OCGN?

Do analysts recommend ANIX or OCGN?

Is ANIX or OCGN more profitable?

Do institutionals and insiders hold more shares of ANIX or OCGN?

Does the media prefer ANIX or OCGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX vs. The Competition

Anixa Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools